Desire is built from hormones, blood flow, mood, sleep, comfort during sex and the state of a relationship. Bloodwork explains part of that picture and helps rule some things in or out. It cannot measure wanting.
Most of the reasons desire falls during the menopause transition are not lab findings at all. They are sleep, stress, pain, mood, medication and the ordinary load of midlife, and they tend to arrive together rather than one at a time.
Sleep is usually the first domino. Night sweats and hot flushes fragment sleep, and fragmented sleep is associated with lower energy, flatter mood and less interest in sex. Clinical reviews of perimenopausal and menopausal symptoms describe vasomotor symptoms, sleep disturbance and mood changes as a cluster rather than separate complaints, which is why fixing one often moves the others[1].
Stress and training load matter next. Long stretches of psychological stress, heavy caregiving weeks and very high training volumes with low food intake all compete with desire for the same limited capacity. Chronic underfuelling is a common and overlooked one. A body that is short on energy tends to down-regulate reproductive signalling long before anything looks abnormal on a report.
Pain and dryness deserve their own line. Falling estrogen thins and dries vulvovaginal tissue for many women, and sex that hurts, or that the body expects to hurt, suppresses desire quickly. Reviews of female sexual function describe desire, arousal, orgasm and pain as linked rather than independent problems, so comfort is part of the desire question, not a separate one[2].
Mood, relationship and context do a lot of the work too. Depression, anxiety, relationship distress and body image concerns are all strongly associated with reduced desire during the menopause years[3]. Never stop a prescribed medicine on your own. Ask the prescriber whether a change is reasonable in your situation.
Finally, life stage sets the backdrop. The menopause transition often begins with cycle changes and symptoms years before the final period, so the hormonal environment can be shifting while cycles still look roughly regular[4]. Alcohol is worth an honest audit as well, since it is associated with lighter, more broken sleep and worse night sweats for many people.
Six markers do most of the useful work here. They are estradiol, total testosterone, SHBG, FSH, TSH and prolactin, and together they describe the hormonal environment that sits underneath desire without ever defining it.
| Marker | Why it is linked to low desire | What a result can and cannot tell you |
|---|---|---|
| Estradiol | The main estrogen, supporting genital blood flow, lubrication and tissue comfort, and influencing sleep and hot flushes | Shows where you sit in the transition on the day of the draw. It cannot measure desire or predict how sex feels |
| Total testosterone | Women produce testosterone in the ovaries and adrenal glands, and production falls gradually with age | Shows whether androgen production is low for your age. A number does not define a desire problem or decide any therapy |
| SHBG | Binds testosterone and estradiol, so it sets how much is free and active. It rises with oral estrogen | Explains why total testosterone can look unremarkable while free testosterone is low. It cannot be read on its own |
| FSH | Rises as ovarian reserve falls, so it tracks the menopause transition | Supports a picture of perimenopause or postmenopause. It swings widely in perimenopause, so one value can mislead |
| TSH | Thyroid function shapes energy, mood, cycle regularity and SHBG | Flags an under- or overactive thyroid worth investigating. It does not confirm that thyroid is why desire changed |
| Prolactin | High prolactin suppresses the reproductive hormone axis and is associated with reduced desire | A single raised value is often explained by stress or timing. Repeat and further testing are decided by a clinician |
The ranges printed beside your results are typical reference ranges for the testing laboratory, and they vary by lab, assay, age, sex and, before menopause, by cycle day. Read your numbers against the range on your own report, then ask a clinician what they mean in your context.
Yes, and it usually acts through comfort and sleep rather than through desire directly. Estradiol supports blood flow to genital tissue, natural lubrication and the elasticity and thickness of the vaginal wall. As levels fall across the transition, many women notice dryness, friction and discomfort first, and reduced interest second. Research on menopause and sexuality describes this pattern repeatedly, with genitourinary changes and sexual difficulties rising together as estrogen declines[3].
There is a second, indirect route. Lower and more erratic estradiol is associated with hot flushes and night sweats, those disrupt sleep, and poor sleep drags mood and energy down with it[1]. Two women with similar estradiol results can therefore feel completely different, because one of them is sleeping through the night and the other is not.
Plenty of things besides menopause move this marker. In perimenopause estradiol can swing from high to low within the same cycle, so a single draw captures one moment rather than a trend. Hormonal contraception, pregnancy, body composition, some medications and differences between laboratory assays all shift the number as well. That is why a result is read as one observation in a longer story, not as a verdict.
Women do produce and use testosterone, and it is the androgen most often discussed in relation to sexual desire. The ovaries and adrenal glands make it throughout adult life, and production declines gradually with age rather than dropping sharply at the final period, which is why levels in your forties are often already lower than they were in your twenties[5]. Clinical reviews describe androgens as contributing to desire, arousal, mood, muscle and bone, with effects that extend well beyond sex[6],[7].
The established picture is narrower than the internet suggests. A systematic review and meta-analysis of randomised controlled trial data found that systemic testosterone in postmenopausal women was associated with improvements in sexual desire, arousal and satisfying sexual events compared with placebo[8]. An international clinical practice guideline reached a similar conclusion for postmenopausal women with hypoactive sexual desire disorder, while being explicit that the evidence base outside that group is thin[9]. More recent clinical summaries continue to frame this as a carefully selected, clinician-supervised option with monitoring, not a general supplement for midlife[10],[11].
Here is the part that surprises people. Blood testosterone levels correlate poorly with how much desire a woman reports, and guidelines state that a testosterone level should not be used by itself to diagnose low desire[9]. Many routine immunoassays are also imprecise at the low concentrations typical in women, so the method matters. A Testosterone Total result is useful for building context and for safety monitoring, and it is not a desire score. Any decision about hormone therapy of any kind is made by a licensed provider who evaluates whether it is appropriate for you, after reviewing your history, your symptoms and your full results.
SHBG decides how much of your testosterone is free to act, so it can make a normal-looking total testosterone misleading. Sex hormone binding globulin is a transport protein that binds testosterone tightly and estradiol more loosely. When SHBG is high, more of the hormone is bound and less is available to tissue, even though the total is unchanged.
This is not a rare quirk. Oral estrogen raises SHBG substantially because it passes through the liver first, which is one reason the route of hormone therapy changes the hormonal picture, and clinical reviews of androgens in menopause describe this effect clearly[5]. Thyroid hormone excess and pregnancy also raise it. Insulin resistance, higher body fat and androgen exposure tend to lower it. Because of that, SHBG is often the marker that makes sense of an otherwise confusing androgen panel[7].
What SHBG cannot do is stand alone. A high or low value is information about hormone availability, not a symptom explanation, and it is interpreted alongside total testosterone, estradiol and the rest of the picture.
FSH tells you roughly where you are in the transition, not why desire changed. Follicle stimulating hormone comes from the pituitary and rises as the ovaries become less responsive, so a persistently elevated FSH with absent periods fits a postmenopausal picture.
The catch is timing. During perimenopause, FSH can be high one month and unremarkable the next, because ovulatory cycles still happen intermittently. Work on the onset of the menopause transition describes cycle variability and symptom onset appearing well before the final period, which is exactly the window in which single hormone measurements are least reliable[4]. For that reason, symptoms and cycle history usually carry more weight than one FSH value in women in their forties.
Other things shift it as well. Hormonal contraception suppresses it, cycle day changes it before menopause, and some pituitary conditions alter it. FSH is a useful orientation marker and a poor desire marker.
Yes, thyroid dysfunction is a recognised and easily missed contributor to low energy, low mood and reduced sexual interest. Thyroid hormone sets metabolic pace in almost every tissue, and both underactive and overactive thyroid states are associated with fatigue, mood changes, cycle irregularity and sexual difficulties. Checking TSH is standard when someone reports new tiredness and low desire, because it is common, measurable and manageable under a clinician's care.
There is a second reason it belongs on this panel. Thyroid status influences SHBG, so an unrecognised thyroid problem can change how your androgen results read. Studies indicate that symptom overlap between thyroid dysfunction and the menopause transition is wide, which is part of why clinicians check thyroid function before concluding that menopause explains everything[1].
Several everyday factors move TSH. Time of day, recent acute illness, pregnancy and high-dose biotin supplements that interfere with some assays can all shift the result. One borderline value is usually repeated rather than acted on.
A genuinely raised prolactin level can lower desire, because prolactin suppresses the signalling that drives ovarian hormone production. When Prolactin stays high, estradiol and testosterone output tends to fall, and reduced sexual interest is one of the recognised consequences. In people with persistently elevated prolactin, clinicians look for a cause rather than assuming menopause.
Most single raised values are not a problem. Prolactin rises with stress, including the stress of the blood draw itself, with nipple stimulation, recent sex, exercise, sleep and the time of day. Several medication classes raise it too, particularly some psychiatric and anti-nausea drugs. A pituitary adenoma is a less common cause and is specifically looked for when values stay high on a properly timed repeat test.
A clearly elevated prolactin that persists, especially alongside milk-like nipple discharge, headaches, absent periods before the expected age or changes in vision, is worth discussing with a clinician promptly. That combination is not something to monitor on your own.
A completely unremarkable panel can sit alongside a real and significant loss of desire, because most of the causes are not measured in blood. Relationship conflict, resentment, grief, caregiving exhaustion, a history of trauma, body image and plain lack of privacy or time never appear on a report, yet they frequently explain more than any hormone does[2].
Physical causes hide from bloodwork too. Genitourinary changes, pelvic floor dysfunction, skin conditions of the vulva and pain with penetration are found on examination, not on a panel. Depression and anxiety are assessed through questions. Untreated sleep apnoea shows up in a sleep study. Medication effects are identified by a prescriber reviewing your list.
Timing is another limit. In perimenopause, hormone levels fluctuate week to week, so a draw taken on a good day can look reassuring while the pattern is anything but steady[4]. History matters as well. Women who reach menopause abruptly after removal of both ovaries experience a sudden fall in both estrogen and androgen production, and reviews of surgical menopause describe sexual symptoms as common and often more pronounced in that group[12]. That context changes how the same numbers are read.
Some symptoms should not wait for a routine appointment. Any vaginal bleeding after menopause needs prompt assessment. So does bleeding after sex, new or worsening pelvic pain, or pain during sex that is getting worse rather than better.
Seek care promptly for milk-like nipple discharge, new persistent headaches or changes in vision, since that combination is assessed alongside prolactin testing. The same applies to rapid unexplained weight change, a racing heartbeat, or severe fatigue that stops you functioning.
Mood symptoms count as red flags too. Low mood that lasts most of the day for weeks, loss of interest in everything rather than sex alone, or hopelessness all deserve prompt professional help. If you are having thoughts of self-harm, call or text 988 (US) or your local emergency number now.
None of this is self-diagnosis territory. Bring the symptoms and any results to a clinician and let them examine, interpret and decide.
All six are measured from one blood draw on a womens hormone menopause panel, which covers estradiol, total testosterone, SHBG, FSH, TSH and prolactin. Timing of the draw is worth planning with a clinician, because results in perimenopause depend on where you are in the cycle.
FitScript members are tested across 150+ biomarkers per year, and Atlas, FitScript's AI health advisor, explains what each result shows in plain language and how the markers relate to each other. Interpretation is the point, since these numbers mean little in isolation. Any treatment, including any hormone therapy, is decided by a licensed provider who evaluates whether it is appropriate after reviewing your history and your results.
This article is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider before changing anything.
Start with the causes that move fastest. Protect sleep, reduce alcohol, address pain or dryness with sex, review medications with the prescriber, and rebuild strength training and food intake if either has slipped. Then check estradiol, testosterone, SHBG, FSH, TSH and prolactin, and review the results with a clinician.
Low desire in perimenopause is common and usually multifactorial. Fluctuating estradiol, broken sleep from night sweats, gradually declining testosterone, stress and mood changes often overlap. Hormone levels swing week to week in this phase, so one blood draw can mislead. Symptoms, cycle history and labs together give a clinician the clearer picture.
After menopause, lower estradiol is associated with vaginal dryness and discomfort, and androgen production has declined gradually with age. Both can reduce desire. Mood, sleep, relationship context and medications matter just as much. Checking estradiol, total testosterone, SHBG, FSH, TSH and prolactin helps a clinician work out which parts apply to you.
Not necessarily. Blood testosterone correlates poorly with reported desire, and guidelines say a level should not be used alone to diagnose low desire. High SHBG can also leave free testosterone low while the total looks unremarkable. The result is context for a clinician, not an answer on its own.
If you still have cycles, timing matters because estradiol and FSH change across the month, so ask the clinician or lab which day suits your situation. After periods have stopped for twelve months, timing is far less important. Prolactin is best drawn in a calm, rested state.
Hormone therapy may help indirectly by easing hot flushes, sleep disruption and vaginal dryness, and systemic testosterone is associated with improved desire in selected postmenopausal women. Suitability depends on your history and risks, so a licensed provider evaluates whether any hormone therapy is appropriate.
Pain is assessed in its own right, because desire falls quickly when the body expects discomfort. Vulvovaginal tissue changes, pelvic floor problems and skin conditions are found on examination rather than in blood. See a clinician for assessment, and mention pain explicitly rather than describing it only as low libido.
That depends on the findings and on whether anything changes in your care, so a clinician sets the interval. Borderline or unexpected results are often repeated before conclusions are drawn, particularly prolactin and TSH. Tracking markers over time usually gives a more useful picture than a single snapshot.